

# Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration

Skaane P, Bandos A, Gullien R, Eben E, Ekseth U, Haakenaasen U, Izadi M, Jebesen I, Jahr G, Krager M, Hofvind S.



Eur Radiol. 2013 Apr 4

## OBJECTIVE

To compare double readings when interpreting full field digital mammography (2D) and tomosynthesis (3D) during mammographic screening.

## MATERIALS AND METHODS

A prospective screening study is underway. 2D and 3D imaging were performed during the first year on 12,621 consenting women. Four radiologists independently interpreted each examination under 4 reading modes. Analysis was done on the paired double reading of 2D (Arm A+B) and 2D+3D (Arm C+D).

- Arm A – 2D
- Arm B – 2D+CAD
- Arm C – 2D+3D
- Arm D – synthesized 2D+3D

## RESULTS

- Double reading of tomosynthesis-based examinations significantly reduced false-positive interpretations. False-positive interpretations were decreased by 18% using 2D plus tomosynthesis.
- Double reading of tomosynthesis-based examinations significantly increased the detection of breast cancers by approximately 30%. The detection of invasive cancers was increased by approximately 40%.

## KEY FINDINGS

1. Tomosynthesis-based screening was successfully implemented in a large prospective screening trial.
2. Double reading of tomosynthesis-based examinations significantly reduced reduced false-positive interpretations.
3. Double reading of tomosynthesis significantly increased the detection of invasive cancers.

## CONCLUSION

The study results demonstrated that double reading of 2D+3D significantly improves cancer detection rate during mammographic screening.

**HOLOGIC**<sup>®</sup>

The Women's Health Company

MISC-02451 © 2013 Hologic, Inc. All rights reserved.

Hologic, Selenia and Dimensions are trademarks or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/or other countries. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.